CRChristopher A. Reilly

Christopher A. Reilly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christopher A. Reilly has a total of 235 co-authors. Here are the top co-authors by number of shared publications:

  • Cassandra E. Deering-Rice

    University of Utah College of Pharmacy

    12 shared publications
  • Erin G. Romero

    Department of Pharmacology and Toxicology, Center for Human Toxicology, University of Utah, Salt Lake City, Utah

    11 shared publications
  • Garold S. Yost

    Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, Utah (J.K.R., C.D.M., G.S.Y., C.A.R.); and Department of Pediatrics, School of Medicine, University of Utah, Salt Lake City, Utah (R.M.W.)

    11 shared publications
  • Cassandra E. Deering-Rice

    Department of Pharmacology and Toxicology, Center for Human Toxicology, University of Utah, Salt Lake City, Utah

    9 shared publications
  • Joseph E. Rower

    Center for Human Toxicology, Department of Pharmacology and Toxicology, University of Utah , Salt Lake City, Utah

    8 shared publications
  • Marysol Almestica-Roberts

    Department of Pharmacology and Toxicology, University of Utah , Salt Lake City, UT 84112

    8 shared publications

Latest Publications

  • Open Access

    Regulation of transient receptor potential ankyrin-1 agonist–induced airway epithelial cell injury and repair by protein kinase C and p38 mitogen-activated kinase

    by Samantha N. Serna, Erin G. Romero, Shao-En Ong, Martin Golkowski, Lili Sun, Christopher A. Reilly

  • Open Access

    Pharmacokinetics of repeated, high-dose fentanyl administration in rats

    by David P. Obert, Autumn McKnite, Gwi H. Park, Kevin M. Watt, Christopher A. Reilly, Kathleen F. Vincent, Joseph E. Rower, Ken Solt

  • Pediatric oral cavity physiologically based pharmacokinetic model to predict pharmacokinetics of mucoadhesive atropine gel to treat sialorrhea

    by Madison Parrot, Nancy Murphy, Joseph E. Rower, Christopher A. Reilly, Danielle Green, Ariel Tarrell, Kevin Watt, Venkata Yellepeddi

    Sialorrhea significantly impairs quality of life in children with neurodisabilities, including cerebral palsy, yet safe and effective pharmacologic treatment options remain limited. Although atropine is widely used for sialorrhea, it is most commonly used off-label as ophthalmic drops administered intraorally, an approach constrained by poor mucosal retention, frequent dosing, medication-error risk, and systemic anticholinergic adverse effects. To address these limitations, we developed a novel mucoadhesive atropine oral gel (0.01% weight/weight (w/w)) to enhance intraoral residence time and support controlled local and systemic exposure. The pharmacokinetics and safety of the atropine gel were evaluated in a Phase I clinical trial in healthy adults, which informed the development and validation of a physiologically based pharmacokinetic (PBPK) model incorporating a mechanistic oral cavity framework. The oral cavity PBPK model accounts for salivary flow, mucosal absorption, swallowing, and saliva-tissue exchange across six compartments, enabling predictions of local and systemic exposure and evaluation of formulation-relevant determinants of intraoral absorption. Pediatric PBPK simulations were scaled from the adult model using Population Estimates for Age-Related Physiology™ (PEAR Physiology™) to support model-informed dose selection. Simulations identified a minimum pediatric dose range of 0.25 mg/kg once or twice daily, with twice-daily dosing to maintain plasma concentrations within the established minimum effective and maximum tolerated concentration range. Collectively, this work demonstrates the utility of PBPK modeling as a translational tool to integrate formulation attributes, oral cavity physiology, and pediatric dose selection, and supports the clinical advancement of mucoadhesive atropine gel as a safer alternative to off-label intraoral atropine eye drops.

  • Open Access

    CYP1B1 modulates stress and repair pathways in airway cells challenged by wood smoke particles

    by Lili Sun, Marysol Almestica-Roberts, Nam D Nguyen, Jacob Cowley, Erin Gail Romero, Samantha N Serna, Peng Zhang, Changshan Niu, Tosifa A Memon, Cassandra E Deering-Rice, et al.

    Environmental pollution negatively impacts respiratory health by damaging and reprogramming airway epithelial cells (AECs). CYP1B1 is one of the most highly induced genes in AECs exposed to combustion-derived air pollutants such as wood smoke particulate matter (WSPM) and plays dual roles in generating toxic reactive intermediates and in the detoxification of xenobiotics of diverse nature. However, the significance of CYP1B1 induction by AECs challenged with pollutants remains unclear. A comparison of BEAS-2B and CYP1B1-overexpressing BEAS-2B cells revealed that CYP1B1 overexpression reduced acute cytotoxicity and enhanced proliferation and migration following WSPM-induced injury in vitro. Conversely, inhibition of CYP1B1 in HBEC3-KT cells increased cytotoxicity and decreased proliferation. CYP1B1 inhibition in HBEC3-KT cells exacerbated endoplasmic reticulum stress (ERS), which promotes cell cycle arrest and cytotoxicity, while overexpression of CYP1B1 attenuated ERS. CYP1B1 Inhibition also enhanced the expression of mRNA for the NRF2 target genes NQO1 and HMOX1, and the proinflammatory cytokine IL8, whereas CYP1B1 overexpression downregulated mRNA expression for NQO1 and HMOX1. In vivo, Cyp1b1-deficient mice exhibited greater basal lung inflammation, but limited response to WSPM-treatment compared with wild-type mice. However, Cyp1b1−/− derived mouse tracheal epithelial cells treated with WSPM showed a more pronounced inflammatory response, characterized by exacerbated Cxcl1, Cxcl2, and Trpa1 mRNA expression compared with wild-type cells. In conclusion, CYP1B1 mitigates WSPM-induced damage to AECs by squelching ERS, oxidative stress, NRF2, and inflammatory signaling, thereby supporting cellular defense and repair. Additional interactions with CYP1A1 and TRP channels also suggest a broader role in AEC physiology.

  • Open Access

    Carnosic acid in topical rosemary extract enhances skin repair via TRPA1 activation

    by Emmanuel Rapp, Jiayi Pang, Borna Saeednia, Stephen Marsh Prouty, Christopher A. Reilly, Thomas H. Leung

    Mammalian skin wounds typically heal with a scar, characterized by fibrotic tissue that disrupts original tissue architecture and function. Therapies that limit fibrosis and promote regenerative healing remain a major unmet clinical need. Rosemary extract, particularly in the form of topical oils and creams, has gained widespread public attention for its purported wound-healing properties. However, its efficacy and mechanism of action remain poorly understood. We show in adult wound healing mouse models that an ethanol-based rosemary extract accelerates the speed of wound healing and mitigates fibrosis. Mechanistically, we identify that carnosic acid, a major bioactive component of rosemary leaves, activates the transient receptor potential ankyrin 1 (TRPA1) nociceptor on cutaneous sensory neurons to enhance tissue regeneration. Mice lacking TRPA1 in sensory neurons do not exhibit these pro-regenerative responses, confirming its role as a critical mediator. Together, these findings suggest that topical rosemary extract may represent an effective and accessible therapeutic approach to improve skin repair outcomes.


  • Open Access

    Development of a preclinical testing platform for clinically relevant therapy for Dravet syndrome

    by Jeffrey A. Mensah, Kyle E. Thomson, Jennifer L. Huff, Tia Freeman, Christopher A. Reilly, Joseph E. Rower, Cameron S. Metcalf, Karen S. Wilcox

    Objective: Patients with drug‐resistant epilepsy, including Dravet syndrome, are frequently prescribed multiple antiseizure medications. Nevertheless, people with Dravet syndrome often have inadequate seizure control, and there is an ongoing unmet clinical need to identify novel therapeutics. As a proof‐of‐principle study to further validate and characterize the Scn1a A1783V/WT mouse model and identify a drug‐testing paradigm with face, construct, and predictive validity, we assessed the efficacy of subchronic administration of stiripentol add‐on to clobazam and valproic acid at clinically relevant doses using the Scn1a A1783V/WT mouse model. Methods: Following a 14‐day treatment, we evaluated the efficacy of stiripentol add‐on to clobazam and valproic acid using hyperthermia‐induced ( n = 6) and video‐electroencephalography (EEG) monitoring of spontaneous seizure tests ( n = 13). Valproic acid was delivered via osmotic minipump, whereas stiripentol and clobazam were administered via food pellets delivered through automatic feeders. Bioanalytical assays were performed to evaluate drug concentrations in plasma and brain using liquid chromatography–tandem mass spectrometry. Results: Stiripentol, clobazam, N ‐desmethylclobazam, and valproic acid all yielded plasma concentrations within the therapeutic plasma concentration range for humans. Stiripentol added to clobazam and valproic acid significantly elevated the seizing temperatures in the hyperthermia‐induced seizure assay (** p = 0.0018; Log‐rank test). Clobazam, valproic acid, and stiripentol co‐administration significantly reduced spontaneous seizure frequency compared to clobazam and valproic acid combined (*** p = 0.0003, Mann–Whitney test). Significance: This research lays the groundwork for exploring effective add‐on compounds to clobazam and valproic acid in treating Dravet syndrome. The study further highlights the utility of the Scn1a A1783V/WT mice in discovering therapies for Dravet syndrome–associated pharmacoresistant seizures.


  • Open Access

    Bryostatins 1 and 3 inhibit TRPM8 and modify TRPM8- and TRPV1-mediated lung epithelial cell responses to a proinflammatory stimulus via protein kinase C

    by Lili Sun, John G. Lamb, Changshan Niu, Samantha N. Serna, Erin Gail Romero, Cassandra E. Deering-Rice, Eric W. Schmidt, Martin Golkowski, Christopher A. Reilly


  • Validation studies and multiomics analysis of Zhx2 as a candidate quantitative trait gene underlying brain oxycodone metabolite (oxymorphone) levels and behavior

    by William B. Lynch, Sophia A. Miracle, Stanley I. Goldstein, Jacob A. Beierle, Rhea Bhandari, Ethan T. Gerhardt, Ava Farnan, Binh-Minh Nguyen, Kelly K. Wingfield, Ida Kazerani, et al.


  • Parenchymal and inflammatory responses to ozone exposure in the aging healthy and surfactant protein C mutant lung

    by Jenna R. Cheminant, Cassandra E. Deering-Rice, Christopher B. Massa, Ujjwal Adhikari, Jessica Noll, Christopher A. Reilly, Alessandro Venosa

    Environmental stress and genetic mutations in key functional nodes are linked to the pathogenesis and exacerbation of respiratory pathologies. These responses are exacerbated by aging, though the impact of these factors in combination is not clearly defined. Using a surfactant protein-C mutant line, our studies describe structural changes and phenotypic responses triggered by acute ozone exposure in the young/middle-aged/old lung. Spatial transcriptomics also found regionally distinct and enhanced activation in the aged lung.


  • Open Access

    Pro-inflammatory effects of inhaled Great Salt Lake dust particles

    by Jacob M. Cowley, Cassandra E. Deering-Rice, John G. Lamb, Erin G. Romero, Marysol Almestica-Roberts, Samantha N. Serna, Lili Sun, Kerry E. Kelly, Ross T. Whitaker, Jenna Cheminant, et al.

    Climate change and human activities have caused the drying of marine environments around the world. An example is the Great Salt Lake in Utah, USA which is at a near record low water level. Adverse health effects have been associated with exposure to windblown dust originating from dried lakebed sediments, but mechanistic studies evaluating the health effects of these dusts are limited. Monitoring data and images highlight the impact of local crustal and Great Salt Lake sediment dusts on the Salt Lake Valley/Wasatch front airshed. Great Salt Lake sediment and derived PM< 3.1 (quasi-PM2.5 or qPM2.5) contained metals/salts, natural and anthropogenic chemicals, and bacteria. Exposure of mice via inhalation and oropharyngeal aspiration caused neutrophilia, increased expression of mRNA for Il6, Cxcl1, Cxcl2, and Muc5ac in the lungs, and increased IL6 and CXCL1 in bronchoalveolar lavage. Inhaled GSLD qPM2.5 caused a greater neutrophilic response than coal fly ash qPM2.5 and was more cytotoxic to human airway epithelial cells (HBEC3-KT) in vitro. Pro-inflammatory biomarker mRNA induction was replicated in vitro using HBEC3-KT and differentiated monocyte-derived (macrophage-like) THP-1 cells. In HBEC3-KT cells, IL6 and IL8 (the human analogue of Cxcl1 and Cxcl2) mRNA induction was attenuated by ethylene glycol-bis(β-aminoethyl ether)-N, N,N′,N’-tetraacetic acid (EGTA) and ruthenium red (RR) co-treatment, and by TRPV1 and TRPV3 antagonists, but less by the Toll-like Receptor-4 (TLR4) inhibitor TAK-242 and deferoxamine. Accordingly, GSLD qPM2.5 activated human TRPV1 as well as other human TRP channels. Dust from the Salton Sea playa (SSD qPM2.5) also stimulated IL6 and IL8 mRNA expression and activated TRPV1 in vitro, but inhibition by TRPV1 and V3 antagonists was dose dependent. Alternatively, responses of THP-1 cells to the Great Salt Lake and Salton Sea dusts were partially mediated by TLR4 as opposed to TRPV1. Finally, “humanized” Trpv1N606D mice exhibited greater neutrophilia than C57Bl/6 mice following GSLD qPM2.5 inhalation. Dust from the GSL playa and similar dried lakebeds may affect human respiratory health via activation of TRPV1, TRPV3, TLR4, and oxidative stress.